Monthly shot may thwar t opi­oids

The Hazleton Standard-Speaker - - FRONT PAGE - CARLA K. JOHN­SON AP MED­I­CAL WRITER

CHICAGO — The first U.S. study to com­pare two treat­ments for opi­oid ad­dic­tion finds a monthly shot works as well as a daily drug to pre­vent re­lapse.

The shot re­quires days of detox first and that proved to be a stum­bling block for many. For those who made it past that hur­dle, the shot Viv­it­rol worked about the same as an older treat­ment, Subox­one.

Both drugs had high re­lapse rates and there were over­doses, in­clud­ing fa­tal ones, in the ex­per­i­ment in 570 adults. The study, pub­lished Tues­day in the journal Lancet, is the first to com­pare the two drugs in the United States, where an opi­oid ad­dic­tion epi­demic has doc­tors and pol­i­cy­mak­ers dee ply di­vided over treat­ment strate­gies.

Many ad­dic­tion treat­ment pro­grams don’t of­fer ei­ther med­i­ca­tion, or only one of them.

“Let’s not kee p ar­gu­ing about the ex­act bat­ting av­er­ages of these two things,” and make them more

avail­able, said study coau­thor Dr. Joshua Lee of New York Univer­sity School of Medicine.

Pres­i­dent Don­ald Trump re­cently de­clared the cri­sis a na­tional pub­lic health emer­gency. Over doses, most in­volv­ing pre­scrip­tion painkillers and other opi­oids, killed 64,000 peo­ple in the United States last year.

“Ad­dic­tion medicine physi­cians are hung ry to get data, es­pe­cially from head-to­head com­par­isons like this one,” said Dr. Joseph Gar­bely of Penn­syl­va­nia-based Caron Treat­ment Cen­ters, who wasn’t in­volved in the re­search.

A smaller Nor­we­gian study, pub­lished last month, also found the two med­i­ca­tions work equally well.

The new study re­cruited users of heroin and pain pills from eight detox cen­ters across the United States. Half were as­signed to get monthly shots of Viv­it­rol, which con­tains ex­tend­e­drelease nal­trex­one. The oth­ers got daily Subox­one, a bu pr en or phi ne-n al ox one combo in a film that dis­solves un­der the tongue.

Af­ter six months of out­pa­tient treat­ment, in­clud­ing vol­un­tary coun­sel­ing ,65 per­cent of the Viv­it­rol group had re­lapsed com­pared to 57 per­cent of the Sub ox one group. Any­one who dropped out of the study was scored as hav­ing re­lapsed.

The dif­fer­ence in the groups stemmed al­most en­tirely from pa­tients who left dur­ing detox for Viv­it­rol. Twenty-eight per­cent dropped out be­fore get­ting Viv­it­rol, com­pared to 6 per­cent who dropped out be­fore a first dose of Subox­one.

Of those who ac­tu­ally started treat­ment, about half of both groups re­lapsed.

Viv­it­rol re­quires a pa­tient to fully detox first be­cause, if taken too soon, it can cause se­vere and sud­den with­drawal symp­toms. Subox­one can be started sooner, while pa­tients still have mild with­drawal symp­toms.

The re­searchers found no real dif­fer­ence in over­doses. There were five fa­tal over­doses, two in the Viv­it­rol group and three in the Subox­one group. There were 23 non­fa­tal over­doses, 16 in the Viv­it­rol group — half of those in the drop outs who never re­ceived Viv­it­rol — and seven in the Subox­one group.

The two medicines work dif­fer­ently, but both block the pow­er­ful high of ad­dic­tive opi­oids. Treat­ment pro­grams tend to fa­vor one over an­other. Those pre­fer­ring Subox­one com­pare it to in­sulin for di­a­betes, but oth­ers see it as a crutch be­cause it con­tains an opi­oid that has a mild ef­fect on pain and mood. Subox­one costs about $100 a month. Viv­it­rol costs about $1,000 a month.

Methadone, a third treat­ment drug, was not part of the study. In the U.S., methadone must be given at spe­cial clin­ics. Any doc­tor can pre­scribe Viv­it­rol. Pre­scribers need spe­cial train­ing and a waiver to pre­scribe Subox­one.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.